TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.22/5395 |
Resumo: | Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers. Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carcinomas (DTCs). Design: This was a retrospective observational study. Setting and Patients: We studied 647 tumors and tumor-like lesions. A total of 469 patients with FCDTC treated and followed in five university hospitals were included. Mean follow-up (±SD) was 7.8 ± 5.8 years. Main Outcome Measures: Predictive value of TERT promoter mutations for distant metastasization, disease persistence at the end of follow-up, and disease-specific mortality. Results: TERT promoter mutations were found in 7.5% of papillary carcinomas (PTCs), 17.1% of follicular carcinomas, 29.0% of poorly differentiated carcinomas, and 33.3% of anaplastic thyroid carcinomas. Patients with TERT-mutated tumors were older (P < .001) and had larger tumors (P = .002). In DTCs, TERT promoter mutations were significantly associated with distant metastases (P < .001) and higher stage (P < .001). Patients with DTC harboring TERT promoter mutations were submitted to more radioiodine treatments (P = .009) with higher cumulative dose (P = .004) and to more treatment modalities (P = .001). At the end of follow-up, patients with TERT-mutated DTCs were more prone to have persistent disease (P = .001). TERT promoter mutations were significantly associated with disease-specific mortality [in the whole FCDTC (P < .001)] in DTCs (P < .001), PTCs (P = .001), and follicular carcinomas (P < .001). After adjusting for age at diagnosis and gender, the hazard ratio was 10.35 (95% confidence interval 2.01–53.24; P = .005) in DTC and 23.81 (95% confidence interval 1.36–415.76; P = .03) in PTCs. Conclusions: TERT promoter mutations are an indicator of clinically aggressive tumors, being correlated with worse outcome and disease-specific mortality in DTC. TERT promoter mutations have an independent prognostic value in DTC and, notably, in PTC. |
id |
RCAP_5b0eef0e6ba64227a05282da13b97d82 |
---|---|
oai_identifier_str |
oai:recipp.ipp.pt:10400.22/5395 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomasContext: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers. Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carcinomas (DTCs). Design: This was a retrospective observational study. Setting and Patients: We studied 647 tumors and tumor-like lesions. A total of 469 patients with FCDTC treated and followed in five university hospitals were included. Mean follow-up (±SD) was 7.8 ± 5.8 years. Main Outcome Measures: Predictive value of TERT promoter mutations for distant metastasization, disease persistence at the end of follow-up, and disease-specific mortality. Results: TERT promoter mutations were found in 7.5% of papillary carcinomas (PTCs), 17.1% of follicular carcinomas, 29.0% of poorly differentiated carcinomas, and 33.3% of anaplastic thyroid carcinomas. Patients with TERT-mutated tumors were older (P < .001) and had larger tumors (P = .002). In DTCs, TERT promoter mutations were significantly associated with distant metastases (P < .001) and higher stage (P < .001). Patients with DTC harboring TERT promoter mutations were submitted to more radioiodine treatments (P = .009) with higher cumulative dose (P = .004) and to more treatment modalities (P = .001). At the end of follow-up, patients with TERT-mutated DTCs were more prone to have persistent disease (P = .001). TERT promoter mutations were significantly associated with disease-specific mortality [in the whole FCDTC (P < .001)] in DTCs (P < .001), PTCs (P = .001), and follicular carcinomas (P < .001). After adjusting for age at diagnosis and gender, the hazard ratio was 10.35 (95% confidence interval 2.01–53.24; P = .005) in DTC and 23.81 (95% confidence interval 1.36–415.76; P = .03) in PTCs. Conclusions: TERT promoter mutations are an indicator of clinically aggressive tumors, being correlated with worse outcome and disease-specific mortality in DTC. TERT promoter mutations have an independent prognostic value in DTC and, notably, in PTC.We acknowledge GENZYME for funding our work through a research project. This study was supported by the Portuguese Foundation for Science and Technology through PhD Grant SFRH/BD/81940/2011 (to J.V.); PhD Grant SFRH/BD/87887/2012 (to C.T.); PhD Grant SFRH/BD/79135/2011 (to A.A.); and the Scientific Investigation Project PIC/IC/83037/2007. Further funding was obtained from the project “Microenvironment, Metabolism and Cancer,” partially supported by Programa Operacional Regional do Norte (ON.2-O Novo Norte), under the Quadro de Referência Estratégico Nacional, and through the European Regional Development Fund. The work of J.M.C.-T. was supported by Grant PI12/00749-FEDER from the Instituto de Salud Carlos III, the Ministry of Economy and Competitiveness (Madrid, Spain). The Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) is an associate laboratory of the Portuguese Ministry of Science, Technology, and Higher Education, which is partially supported by the Foundation for Science and Technology.R. Paul RobertsonRepositório Científico do Instituto Politécnico do PortoMelo, MiguelGaspar Da Rocha, AdrianaVinagre, JoãoBatista, RuiPeixoto, JoanaTavares, CatarinaCelestino, RicardoAlmeida, AnaSalgado, CatarinaEloy, CatarinaCastro, PatríciaPrazeres, HugoLima, JorgeAmaro, TeresinaLobo, CláudiaMartins, Maria JoãoMoura, MargaridaCavaco, BrancaLeite, ValerianoCameselle-Teijeiro, JoséCarrilho, FranciscoCarvalheiro, ManuelaMaximo, ValdemarSobrinho-Simões, ManuelSoares, Paula2015-01-13T11:38:41Z2014-052014-05-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.22/5395engMelo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., Castro, P., Prazeres, H., Lima, J., Amaro, T., Lobo, C., Martins, M. J., Moura, M., Cavaco, B., Leite, V., … Soares, P. (2014). TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. The Journal of Clinical Endocrinology & Metabolism, 99(5), E754–E765. https://doi.org/10.1210/jc.2013-373410.1210/jc.2013-3734info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-20T01:52:36Zoai:recipp.ipp.pt:10400.22/5395Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:26:03.470164Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
title |
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
spellingShingle |
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas Melo, Miguel |
title_short |
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
title_full |
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
title_fullStr |
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
title_full_unstemmed |
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
title_sort |
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas |
author |
Melo, Miguel |
author_facet |
Melo, Miguel Gaspar Da Rocha, Adriana Vinagre, João Batista, Rui Peixoto, Joana Tavares, Catarina Celestino, Ricardo Almeida, Ana Salgado, Catarina Eloy, Catarina Castro, Patrícia Prazeres, Hugo Lima, Jorge Amaro, Teresina Lobo, Cláudia Martins, Maria João Moura, Margarida Cavaco, Branca Leite, Valeriano Cameselle-Teijeiro, José Carrilho, Francisco Carvalheiro, Manuela Maximo, Valdemar Sobrinho-Simões, Manuel Soares, Paula |
author_role |
author |
author2 |
Gaspar Da Rocha, Adriana Vinagre, João Batista, Rui Peixoto, Joana Tavares, Catarina Celestino, Ricardo Almeida, Ana Salgado, Catarina Eloy, Catarina Castro, Patrícia Prazeres, Hugo Lima, Jorge Amaro, Teresina Lobo, Cláudia Martins, Maria João Moura, Margarida Cavaco, Branca Leite, Valeriano Cameselle-Teijeiro, José Carrilho, Francisco Carvalheiro, Manuela Maximo, Valdemar Sobrinho-Simões, Manuel Soares, Paula |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Politécnico do Porto |
dc.contributor.author.fl_str_mv |
Melo, Miguel Gaspar Da Rocha, Adriana Vinagre, João Batista, Rui Peixoto, Joana Tavares, Catarina Celestino, Ricardo Almeida, Ana Salgado, Catarina Eloy, Catarina Castro, Patrícia Prazeres, Hugo Lima, Jorge Amaro, Teresina Lobo, Cláudia Martins, Maria João Moura, Margarida Cavaco, Branca Leite, Valeriano Cameselle-Teijeiro, José Carrilho, Francisco Carvalheiro, Manuela Maximo, Valdemar Sobrinho-Simões, Manuel Soares, Paula |
description |
Context: Telomerase promoter mutations (TERT) were recently described in follicular cell-derived thyroid carcinomas (FCDTC) and seem to be more prevalent in aggressive cancers. Objectives: We aimed to evaluate the frequency of TERT promoter mutations in thyroid lesions and to investigate the prognostic significance of such mutations in a large cohort of patients with differentiated thyroid carcinomas (DTCs). Design: This was a retrospective observational study. Setting and Patients: We studied 647 tumors and tumor-like lesions. A total of 469 patients with FCDTC treated and followed in five university hospitals were included. Mean follow-up (±SD) was 7.8 ± 5.8 years. Main Outcome Measures: Predictive value of TERT promoter mutations for distant metastasization, disease persistence at the end of follow-up, and disease-specific mortality. Results: TERT promoter mutations were found in 7.5% of papillary carcinomas (PTCs), 17.1% of follicular carcinomas, 29.0% of poorly differentiated carcinomas, and 33.3% of anaplastic thyroid carcinomas. Patients with TERT-mutated tumors were older (P < .001) and had larger tumors (P = .002). In DTCs, TERT promoter mutations were significantly associated with distant metastases (P < .001) and higher stage (P < .001). Patients with DTC harboring TERT promoter mutations were submitted to more radioiodine treatments (P = .009) with higher cumulative dose (P = .004) and to more treatment modalities (P = .001). At the end of follow-up, patients with TERT-mutated DTCs were more prone to have persistent disease (P = .001). TERT promoter mutations were significantly associated with disease-specific mortality [in the whole FCDTC (P < .001)] in DTCs (P < .001), PTCs (P = .001), and follicular carcinomas (P < .001). After adjusting for age at diagnosis and gender, the hazard ratio was 10.35 (95% confidence interval 2.01–53.24; P = .005) in DTC and 23.81 (95% confidence interval 1.36–415.76; P = .03) in PTCs. Conclusions: TERT promoter mutations are an indicator of clinically aggressive tumors, being correlated with worse outcome and disease-specific mortality in DTC. TERT promoter mutations have an independent prognostic value in DTC and, notably, in PTC. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-05 2014-05-01T00:00:00Z 2015-01-13T11:38:41Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.22/5395 |
url |
http://hdl.handle.net/10400.22/5395 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Melo, M., da Rocha, A. G., Vinagre, J., Batista, R., Peixoto, J., Tavares, C., Celestino, R., Almeida, A., Salgado, C., Eloy, C., Castro, P., Prazeres, H., Lima, J., Amaro, T., Lobo, C., Martins, M. J., Moura, M., Cavaco, B., Leite, V., … Soares, P. (2014). TERT Promoter Mutations Are a Major Indicator of Poor Outcome in Differentiated Thyroid Carcinomas. The Journal of Clinical Endocrinology & Metabolism, 99(5), E754–E765. https://doi.org/10.1210/jc.2013-3734 10.1210/jc.2013-3734 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
R. Paul Robertson |
publisher.none.fl_str_mv |
R. Paul Robertson |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131354746585088 |